Affinivax Obtains $2,500,000 New Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    Undisclosed Cambridge, MA 02139 USA
  • Company Description
    Affinivax is a biotechnology company developing a novel conjugation technology with the goal of designing vaccines that provide broad protection against challenging diseases afflicting children and adults in both the developing and developed worlds.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The company intends to advance its lead MAPS vaccine targeting Streptococcus pneumoniae (pneumococcus) towards clinical testing.
  • M&A Terms
  • Venture Investor
    Bill & Melinda Gates Foundation

Trending on Xconomy